Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Probe Panel Recognizes Professor’s COI over Glactiv Scandal, but Doubts Whether It Constitutes Bribery
February 24, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
- Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
- Researchers Launch Scientific Society for Oncolytic Virus Therapies
October 31, 2022
- Less than Half of Japan Prefectures Offer SMA Test under Newborn Screening Program: Survey
October 28, 2022
- Japan Expert Sees Lecanemab Initially Treating Only a Few Tens of Thousands of Patients with Immature Care Setup
October 12, 2022
- 3rd COVID-19 Shot for Kids Aged 5-11 Effective as Booster: Infectious Diseases Association
October 5, 2022
- Antimicrobial Use in 2021 Down 31.5% from 2013: Expert
October 5, 2022
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
- University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
- Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
- Japanese Society of Formulary to Support Regional Initiatives: President
August 18, 2022
- High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor
August 5, 2022
- 7 Japan Scientific Societies Issue Proposal on Development of Vaccines, Anti-Infectives
August 3, 2022
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…